Head and Neck Cancer
Erlotinib + Cisplatin/Radiotherapy (UWCC-6106)
A Multicenter Randomized Phase II Study of Erlotinib (Tarceva), Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck
Investigator: Renato G. Martins, MD, MPH; Conditions: Head and Neck Cancer; Status: Recruiting; Study ID: NCT00410826
Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN)
Investigator: Laura Chow; Conditions: Head and Neck Cancer; Status: Recruiting; Study ID: NCT01334177
A Phase II Study of Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory or -Ineligible, Advanced, Squamous Cell Carcinoma of the Head and Neck
Investigator: Laura Q.M. Chow, MD; Conditions: Squamous Cell Carcinoma; Status: Recruiting; Study ID: NCT01009203
Phase 2 Study of Pemetrexed in Combination with Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Investigator: Laura Q.M. Chow, MD; Conditions: Head and Neck Cancer; Status: Recruiting; Study ID: NCT01087970
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Investigator: John Thompson, MD; Conditions: Advanced Non-Hematologic Malignancies, Non Small Cell Lung Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Prostate Cancer; Status: Recruiting; Study ID: NCT00830869
Join Us On